Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE We review the evidence for PI3K pathway activation in TNBC, and clinical trial data for PI3K, AKT and mammalian target of rapamycin inhibitors in TNBC. 31050709 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Metalloprotease-processed CD95L (cl-CD95L) is a soluble cytokine that implements a PI3K/Ca(2+) signaling pathway in triple-negative breast cancer (TNBC) cells. 27367565 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE PI3K/mTOR inhibitors had an additive growth inhibitory effect when combined with genetic or pharmacological AR targeting in AR + TNBC cells. 25103565 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer. 29228721 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Overexpression of SphK1 enhances cell proliferation and invasion in triple-negative breast cancer via the PI3K/AKT signaling pathway. 26857281 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In the present study, we aimed to investigate, the effect of phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathway dual inhibitor, NVP-BEZ235 and Caffeic acid phenyl ester (CAPE) on TNBC cell line (MDA-MB-231), stimulated with TGF-β1 for 14days in vitro. 28528184 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE In this study, we compared the effect of eribulin on the PI3K/AKT/mTOR pathway with other microtubule-targeting agents in TNBC. 31480338 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE AKT3 is an oncogene of known relevance in breast cancer, and as a proof of principle we show that inhibition of phosphoinositide 3-kinase (PI3K) activity, a protein upstream of AKT3, suppressed proliferation in TNBC preneoplastic cells. 28160548 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Different targeted therapies may be necessary for TNBC that involves activation of PI3K/AKT or MAPK pathways. 25009009 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE We also review the aberrant activated signals found in different subgroups of TNBC, including androgen receptor (AR) and PI3K/AKT/mTOR, Notch, Wnt/β-catenin, Hedge-hog, and TGF-β signaling pathways, which play essential roles in multiple development stages of TNBC. 29069872 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE This study provides a preclinical rationale to investigate the therapeutic potential for the combination of PI3K inhibition and eribulin in the difficult to treat TNBC. 31217901 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Integrin β1, myosin light chain kinase and myosin IIA are required for activation of PI3K-AKT signaling following MEK inhibition in metastatic triple negative breast cancer. 27563827 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE TET1 expression correlated with sensitivity to drugs targeting the PI3K-mTOR pathway, and CRISPR-mediated deletion of TET1 in two independent TNBC cell lines resulted in reduced expression of PI3K pathway genes, upregulation of immune response genes, and substantially reduced cellular proliferation, suggesting dependence of oncogenic pathways on TET1 overexpression. 29891505 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE As EGFR/PI3K/Akt pathway proteins are frequently altered in TNBC, we have studied the gene expression of key proteins of this pathway. 28766167 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Poly(ADP‑ribose) polymerase (PARP) inhibitors, phosphatidylinositol 3‑kinase (PI3K) inhibitors and carboplatin (CBP) have demonstrated sufficient efficacy and safety for their use as individual drugs for the treatment of TNBC; however, their effects on TNBC when used as a combination have not been investigated. 30272286 2018
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Curcumin suppresses doxorubicin-induced epithelial-mesenchymal transition via the inhibition of TGF-β and PI3K/AKT signaling pathways in triple-negative breast cancer cells. 24236784 2013
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Mechanistically, DCC-2036 targeted AXL/MET, especially AXL, and regulated the downstream PI3K/Akt-NFκB signaling to exert its antitumor effect in TNBC. 30289981 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Consequently, targeted therapies based on the interaction of PI3K inhibition with BRCA1 mutations or HR deficiency in TNBC may be a promising strategy for the treatment of patients with TNBC. 31804921 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE This review will focus on recent therapeutic innovations for TNBC, including poly-ADP-ribosyl polymerase (PARP) inhibitors, phosphoinositide 3-kinase (PI3K) pathway inhibitors, immune checkpoint inhibitors, and cyclin-dependent kinase (CDK) inhibitors. 31254268 2019
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE The addition of PI3K-mTOR inhibitors to cisplatin or paclitaxel increased the activity of chemotherapy in the TNBC and LGSOC models; whereas no added activity was observed in the LADC model. 29156674 2017
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE We show in TNBC cells that PI3K inhibition leads to DNA damage, downregulation of BRCA1/2, gain in poly-ADP-ribosylation, and subsequent sensitization to PARP inhibition. 22915752 2012
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Thus, Torin2 and its chemical analogs represent a mechanistically distinct class of PI3K pathway inhibitors that are uniquely cytotoxic to TNBC cells. 31812693 2020
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE Inhibition of the PI3K/mTOR pathway in TNBC cell lines decreased notably the expression of the AR. 24779793 2014
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 AlteredExpression disease BEFREE Expression analysis of the panel of TNBC cell lines indicates that the expression levels of IGF2BP3 can be used as a potential predictor for sensitivity to the PI3K/IGF1R inhibitor combination. 27196766 2016
Entrez Id: 5293
Gene Symbol: PIK3CD
PIK3CD
0.100 Biomarker disease BEFREE We propose that combining PI3K inhibition with anti-PD1 may be a viable therapeutic approach for triple-negative breast cancer.<i></i>. 28003307 2017